Author:
Dutta Shouma,Ahmad Yasmeen
Abstract
The crucial role of T cells in the pathogenesis of rheumatoid arthritis (RA) is well recognized. Tacrolimus is an immunomodulator that acts by the inhibition of T-cell activation. There have been numerous studies examining the use of tacrolimus in RA, including four randomized controlled trials. This article reviews these data with respect to the efficacy of the use of tacrolimus in RA as monotherapy and as part of combination therapy. The safety of tacrolimus use in RA is then evaluated. Tacrolimus is shown to be an effective and safe therapeutic option for RA patients intolerant of or resistant to previous disease-modifying antirheumatic drugs (DMARDs). In addition to monotherapy, tacrolimus has been successfully used as part of combination RA therapy, in particular in conjunction with methotrexate. Further assessment of combination approaches involving tacrolimus use alongside other DMARDs or biologics would be helpful. More studies are required to examine the effects of tacrolimus on the radiographic progression of RA.
Subject
Orthopedics and Sports Medicine,Rheumatology
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献